{"protocolSection": {"identificationModule": {"nctId": "NCT02036515", "orgStudyIdInfo": {"id": "8835-006"}, "secondaryIdInfos": [{"id": "2013-003697-26", "type": "EUDRACT_NUMBER"}, {"id": "B1521015", "type": "OTHER", "domain": "Pfizer Study Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)", "officialTitle": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-06-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-06-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-01-13", "studyFirstSubmitQcDate": "2014-01-13", "studyFirstPostDateStruct": {"date": "2014-01-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-05-19", "resultsFirstSubmitQcDate": "2017-06-23", "resultsFirstPostDateStruct": {"date": "2017-07-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-15", "lastUpdatePostDateStruct": {"date": "2018-09-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin. The primary objective of the trial is to assess the hemoglobin A1C (A1C)-lowering efficacy of the addition of ertugliflozin compared to the addition of placebo with an underlying hypothesis that addition of treatment with ertugliflozin provides greater reduction in A1C compared with the addition of placebo; the primary objective will be tested for both 5-mg and 15-mg doses of ertugliflozin.", "detailedDescription": "The duration of the trial will be approximately 69 weeks. This will include a 1-week Screening Period, an up to 12-week wash-off/titration /dose-stabilization period, a 2-week single-blind, placebo run-in period, a 52-week double-blind, placebo-controlled treatment period (including a 26-week Phase A and 26-week Phase B), and a post-treatment telephone contact 14 days after the last dose of blinded investigational product."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 464, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ertugliflozin 5 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks", "interventionNames": ["Drug: Ertugliflozin 5 mg", "Drug: Metformin", "Drug: Sitagliptin", "Drug: Glimepiride", "Biological: Insulin", "Drug: Placebo for ertugliflozin 10 mg"]}, {"label": "Ertugliflozin 15 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks", "interventionNames": ["Drug: Ertugliflozin 15 mg", "Drug: Metformin", "Drug: Sitagliptin", "Drug: Glimepiride", "Biological: Insulin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks", "interventionNames": ["Drug: Placebo for ertugliflozin 5 mg", "Drug: Metformin", "Drug: Sitagliptin", "Drug: Glimepiride", "Biological: Insulin", "Drug: Placebo for ertugliflozin 10 mg"]}], "interventions": [{"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks", "armGroupLabels": ["Ertugliflozin 5 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Ertugliflozin 15 mg", "description": "Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks", "armGroupLabels": ["Ertugliflozin 15 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Placebo for ertugliflozin 5 mg", "description": "Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants are to remain on their stable doses of metformin (oral, \\>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg", "Placebo"], "otherNames": ["Glucophage", "Glucophage XR"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg", "Placebo"], "otherNames": ["JANUVIA\u00ae"]}, {"type": "DRUG", "name": "Glimepiride", "description": "Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg", "Placebo"], "otherNames": ["AMARYL"]}, {"type": "BIOLOGICAL", "name": "Insulin", "description": "Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg", "Placebo"]}, {"type": "DRUG", "name": "Placebo for ertugliflozin 10 mg", "description": "Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks", "armGroupLabels": ["Ertugliflozin 5 mg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C at Week 26", "description": "A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Experiencing An Adverse Event (AE)", "description": "An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "timeFrame": "Up to Week 54"}, {"measure": "Percentage of Participants Discontinuing Study Treatment Due to an AE", "description": "An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "timeFrame": "Up to Week 52"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26", "description": "The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Body Weight at Week 26", "description": "The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26", "description": "A1C is measured as percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26", "description": "The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Hemoglobin A1C at Week 52", "description": "A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in FPG at Week 52", "description": "The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Body Weight at Week 52", "description": "The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52", "description": "A1C is measured as percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Week 52"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 52", "description": "The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26", "description": "The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 52", "description": "The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Percentage of Participants Receiving Glycemic Rescue Medication by Week 26", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants Receiving Glycemic Rescue Medication by Week 52", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).", "timeFrame": "Week 52"}, {"measure": "Time to Initiation of Glycemic Rescue by Week 26", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days.", "timeFrame": "Up to Week 26 (plus 30 days for 1 placebo participant)"}, {"measure": "Time to Initiation of Glycemic Rescue by Week 52", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days.", "timeFrame": "Up to week 52"}, {"measure": "Baseline Homeostasis Model Assessment of \u03b2-cell Function (HOMA-%\u03b2) Value", "description": "HOMA-%\u03b2 is a well-accepted means of assessing fasting \u03b2-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%\u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\]", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in HOMA-%\u03b2 at Week 26", "description": "HOMA-%\u03b2 is a well-accepted means of assessing fasting \u03b2-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%\u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\]. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in HOMA-%\u03b2 at Week 52", "description": "HOMA-%\u03b2 is a well-accepted means of assessing fasting \u03b2-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%\u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\]. Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}, {"measure": "Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score", "description": "The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best).", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26", "description": "The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in EQ-5D-3L Score at Week 52", "description": "The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.", "timeFrame": "Baseline and Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus (T2DM)\n* On stable diabetes therapy of metformin with either sitagliptin or another dipeptidyl peptidase-4 (DPP-4) inhibitor or a sulfonylurea (SU) prior to study participation and is willing to wash-off/switch from another DPP-4 inhibitor/SU to sitagliptin\n* Body Mass Index (BMI) greater than or equal to 18.0 kg/m\\^2\n* Male, postmenopausal female or surgically sterile female\n* If a female of reproductive potential, agrees to remain abstinent or to use (or have their partner use) 2 acceptable combinations of birth control while participating in the trial and for 14 days after the last use of study drug\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine disorders, drug- or chemical-induced, and post-organ transplant)\n* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) or DPP-4 inhibitor\n* On a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable\n* Has undergone bariatric surgery within the past 12 months or \\>12 months and is not weight stable\n* Has been treated with insulin (except for short-term use \\[\\<= 7 days\\]), injectable antihyperglycemic agents (AHAs) (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other sodium-glucose co-transporter 2 (SGLT2) inhibitors, alpha glucosidase inhibitors or meglitinides, bromocriptine (Cycloset\u2122), colesevelam (Welchol\u2122), or any other non-protocol approved AHAs within 12 weeks of study participation\n* Has active, obstructive uropathy or indwelling urinary catheter\n* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation\n* A history of malignancy \u22645 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer\n* Known history of Human Immunodeficiency Virus (HIV)\n* Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or any other clinically significant hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n* A medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease\n* Has any clinically significant malabsorption condition\n* If taking thyroid replacement therapy, has not been on a stable dose for at least 6 weeks prior to study participation\n* Has been previously randomized in a study with ertugliflozin\n* Has participated in other studies involving an investigational drug within 30 days prior or during study participation\n* Has undergone a surgical procedure within 6 weeks prior to or planned major surgery during study participation\n* Has a positive urine pregnancy test\n* Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of study medication\n* Planning to undergo hormonal therapy in preparation to donate eggs during the trial, including 14 days following the last dose of study medication\n* Excessive consumption of alcoholic beverages or binge drinking\n* Has donated blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "28921862", "type": "RESULT", "citation": "Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018 Mar;20(3):530-540. doi: 10.1111/dom.13116. Epub 2017 Oct 23."}, {"pmid": "32700393", "type": "DERIVED", "citation": "Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27."}, {"pmid": "32648108", "type": "DERIVED", "citation": "Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9."}, {"pmid": "32372382", "type": "DERIVED", "citation": "Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5."}, {"pmid": "32324082", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13."}, {"pmid": "32324065", "type": "DERIVED", "citation": "Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13."}, {"pmid": "31797522", "type": "DERIVED", "citation": "Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3."}, {"pmid": "31064361", "type": "DERIVED", "citation": "Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Two participants were randomized to Ertugliflozin 15 mg, but did not receive any treatment.", "groups": [{"id": "FG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "FG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "FG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "156"}, {"groupId": "FG001", "numSubjects": "155"}, {"groupId": "FG002", "numSubjects": "153"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "156"}, {"groupId": "FG001", "numSubjects": "153"}, {"groupId": "FG002", "numSubjects": "153"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "151"}, {"groupId": "FG001", "numSubjects": "143"}, {"groupId": "FG002", "numSubjects": "139"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Screen failure", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Hyperglycemia", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants as treated population excludes two participants randomized to Ertugliflozin 15 mg but did not receive any treatment.", "groups": [{"id": "BG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "BG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "BG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "153"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "462"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.2", "spread": "9.3"}, {"groupId": "BG001", "value": "59.7", "spread": "8.6"}, {"groupId": "BG002", "value": "58.3", "spread": "9.2"}, {"groupId": "BG003", "value": "59.1", "spread": "9.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "75"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "53"}, {"groupId": "BG003", "value": "199"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "82"}, {"groupId": "BG002", "value": "100"}, {"groupId": "BG003", "value": "263"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "description": "Participants with baseline data: ertugliflozin 5 mg, n=155; ertugliflozin 15 mg, n=152; placebo, n=152; total, n=459", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.05", "spread": "0.86"}, {"groupId": "BG001", "value": "8.00", "spread": "0.83"}, {"groupId": "BG002", "value": "8.03", "spread": "0.93"}, {"groupId": "BG003", "value": "8.03", "spread": "0.88"}]}]}]}, {"title": "Fasting plasma glucose", "description": "Participants with baseline data: ertugliflozin 5 mg, n=156; ertugliflozin 15 mg, n=152; placebo, n=152; total, n=460", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "167.7", "spread": "37.7"}, {"groupId": "BG001", "value": "171.7", "spread": "39.1"}, {"groupId": "BG002", "value": "169.6", "spread": "37.8"}, {"groupId": "BG003", "value": "169.7", "spread": "38.2"}]}]}]}, {"title": "Body weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "87.6", "spread": "18.6"}, {"groupId": "BG001", "value": "86.6", "spread": "19.5"}, {"groupId": "BG002", "value": "86.4", "spread": "20.8"}, {"groupId": "BG003", "value": "86.9", "spread": "19.6"}]}]}]}, {"title": "Estimated glomerular filtration rate (eGFR)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "87.0", "spread": "17.5"}, {"groupId": "BG001", "value": "86.9", "spread": "15.6"}, {"groupId": "BG002", "value": "89.9", "spread": "17.5"}, {"groupId": "BG003", "value": "87.9", "spread": "16.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C at Week 26", "description": "A1C is measured as percent. Thus this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one A1C measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.78", "lowerLimit": "-0.91", "upperLimit": "-0.65"}, {"groupId": "OG001", "value": "-0.86", "lowerLimit": "-0.99", "upperLimit": "-0.72"}, {"groupId": "OG002", "value": "-0.09", "lowerLimit": "-0.23", "upperLimit": "-0.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Constrained longitudinal data analysis", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares mean", "paramValue": "-0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.87", "ciUpperLimit": "-0.50"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares mean", "paramValue": "-0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.95", "ciUpperLimit": "-0.58"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Experiencing An Adverse Event (AE)", "description": "An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who took at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 54", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.7"}, {"groupId": "OG001", "value": "60.1"}, {"groupId": "OG002", "value": "63.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-5.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.5", "ciUpperLimit": "5.2"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-3.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.1", "ciUpperLimit": "7.6"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Discontinuing Study Treatment Due to an AE", "description": "An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.", "populationDescription": "Analysis population consisted of all randomized participants who took at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.5"}, {"groupId": "OG001", "value": "3.9"}, {"groupId": "OG002", "value": "3.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "0.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.4", "ciUpperLimit": "5.6"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.9", "ciUpperLimit": "4.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26", "description": "The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one FPG measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-26.91", "spread": "-32.58", "lowerLimit": "-32.58", "upperLimit": "-21.24"}, {"groupId": "OG001", "value": "-33.04", "lowerLimit": "-38.71", "upperLimit": "-27.36"}, {"groupId": "OG002", "value": "-1.76", "lowerLimit": "-7.70", "upperLimit": "4.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Differenc in least squares means", "paramValue": "-25.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.76", "ciUpperLimit": "-17.54"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares means", "paramValue": "-31.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.90", "ciUpperLimit": "-23.66"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 26", "description": "The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one body weight measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.35", "lowerLimit": "-3.78", "upperLimit": "-2.91"}, {"groupId": "OG001", "value": "-3.04", "lowerLimit": "-3.48", "upperLimit": "-2.60"}, {"groupId": "OG002", "value": "-1.32", "lowerLimit": "-1.77", "upperLimit": "-0.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares means", "paramValue": "-2.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.65", "ciUpperLimit": "-1.40"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares means", "paramValue": "-1.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.35", "ciUpperLimit": "-1.09"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 26", "description": "A1C is measured as percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one A1C measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.1"}, {"groupId": "OG001", "value": "39.9"}, {"groupId": "OG002", "value": "17.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Logistic regression model fitted with terms for treatment, baseline A1C, baseline eGFR and prior antihyperglycemic medication.", "paramType": "Odds Ratio (OR)", "paramValue": "3.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.74", "ciUpperLimit": "5.72"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Logistic regression model fitted with terms for treatment, baseline A1C, baseline eGFR and prior antihyperglycemic medication.", "paramType": "Difference in least squares means", "paramValue": "4.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.44", "ciUpperLimit": "8.02"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26", "description": "The change from baseline is the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one systolic blood pressure measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.87", "spread": "0.62", "lowerLimit": "-5.52", "upperLimit": "-2.09"}, {"groupId": "OG001", "value": "130.87", "spread": "0.62", "lowerLimit": "-6.55", "upperLimit": "-3.09"}, {"groupId": "OG002", "value": "130.87", "spread": "0.62", "lowerLimit": "-2.70", "upperLimit": "0.94"}]}]}, {"title": "Change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.81", "spread": "0.87"}, {"groupId": "OG001", "value": "-4.82", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.88", "spread": "0.93"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares means", "paramValue": "-2.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.36", "ciUpperLimit": "-0.49"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "cLDA", "statisticalComment": "Model is fitted with effects for treatment, time, interaction of time by treatment, effects for baseline eGFR and prior antihyperglycemic medication", "paramType": "Difference in least squares means", "paramValue": "-3.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.39", "ciUpperLimit": "-1.50"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Hemoglobin A1C at Week 52", "description": "A1C is measured as percent. Thus this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one A1C measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "lowerLimit": "-0.90", "upperLimit": "-0.59"}, {"groupId": "OG001", "value": "-0.81", "lowerLimit": "-0.97", "upperLimit": "-0.66"}, {"groupId": "OG002", "value": "0.02", "lowerLimit": "-0.15", "upperLimit": "0.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.98", "ciUpperLimit": "-0.54"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.05", "ciUpperLimit": "-0.61"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 52", "description": "The change from baseline is the Week 52 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one FPG measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-25.57", "lowerLimit": "-30.91", "upperLimit": "-20.23"}, {"groupId": "OG001", "value": "-26.38", "lowerLimit": "-31.80", "upperLimit": "-20.97"}, {"groupId": "OG002", "value": "3.19", "lowerLimit": "-3.08", "upperLimit": "9.47"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-28.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.44", "ciUpperLimit": "-21.09"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-29.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.30", "ciUpperLimit": "-21.85"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 52", "description": "The change from baseline is the Week 52 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one body weight measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.46", "lowerLimit": "-4.07", "upperLimit": "-2.85"}, {"groupId": "OG001", "value": "-2.83", "lowerLimit": "-3.45", "upperLimit": "-2.21"}, {"groupId": "OG002", "value": "-0.95", "lowerLimit": "-1.65", "upperLimit": "-0.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-2.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.43", "ciUpperLimit": "-1.59"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-1.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.81", "ciUpperLimit": "-0.95"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With an A1C <7% (53 mmol/Mol) at Week 52", "description": "A1C is measured as percent. Laboratory measurements were performed after an overnight fast \u226510 hours in duration. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one A1C measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "32.7"}, {"groupId": "OG002", "value": "13.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Odds Ratio (OR)", "paramValue": "3.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.98", "ciUpperLimit": "6.64"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Odds Ratio (OR)", "paramValue": "4.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.22", "ciUpperLimit": "7.28"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 52", "description": "The change from baseline is the Week 52 systolic blood pressure minus the Week 0 systolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one systolic blood pressure measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.92", "spread": "0.62", "lowerLimit": "-6.03", "upperLimit": "-2.29"}, {"groupId": "OG001", "value": "130.92", "spread": "0.62", "lowerLimit": "-5.98", "upperLimit": "-2.20"}, {"groupId": "OG002", "value": "130.92", "spread": "0.62", "lowerLimit": "-1.41", "upperLimit": "3.06"}]}]}, {"title": "Change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.16", "spread": "0.95"}, {"groupId": "OG001", "value": "-4.09", "spread": "0.96"}, {"groupId": "OG002", "value": "0.83", "spread": "1.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-4.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.82", "ciUpperLimit": "-2.15"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-4.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.76", "ciUpperLimit": "-2.07"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26", "description": "The change from baseline is the Week 26 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one diastolic blood pressure measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.42", "spread": "0.36", "lowerLimit": "-2.88", "upperLimit": "-0.48"}, {"groupId": "OG001", "value": "78.42", "spread": "0.36", "lowerLimit": "-3.02", "upperLimit": "-0.60"}, {"groupId": "OG002", "value": "78.42", "spread": "0.36", "lowerLimit": "-1.71", "upperLimit": "0.84"}]}]}, {"title": "Change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.68", "spread": "0.61"}, {"groupId": "OG001", "value": "-1.81", "spread": "0.62"}, {"groupId": "OG002", "value": "-0.43", "spread": "0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-1.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.97", "ciUpperLimit": "0.48"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-1.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.11", "ciUpperLimit": "0.36"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 52", "description": "The change from baseline is the Week 52 diastolic blood pressure minus the Week 0 diastolic blood pressure. Sitting blood pressure was measured in triplicate. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one diastolic blood pressure measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.44", "spread": "0.36", "lowerLimit": "-2.72", "upperLimit": "-0.32"}, {"groupId": "OG001", "value": "78.44", "spread": "0.36", "lowerLimit": "-2.59", "upperLimit": "-0.17"}, {"groupId": "OG002", "value": "78.44", "spread": "0.36", "lowerLimit": "-1.97", "upperLimit": "0.91"}]}]}, {"title": "Change from baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.52", "spread": "0.61"}, {"groupId": "OG001", "value": "-1.38", "spread": "0.62"}, {"groupId": "OG002", "value": "-0.53", "spread": "0.73"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.82", "ciUpperLimit": "0.84"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.69", "ciUpperLimit": "0.99"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Receiving Glycemic Rescue Medication by Week 26", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).", "populationDescription": "Analysis population included all randomized participants who took at least one dose of trial treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.3"}, {"groupId": "OG001", "value": "2.0"}, {"groupId": "OG002", "value": "16.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-15.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.9", "ciUpperLimit": "-9.4"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percent", "paramValue": "-14.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.3", "ciUpperLimit": "-8.5"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Receiving Glycemic Rescue Medication by Week 52", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant).", "populationDescription": "Analysis population included all randomized participants who took at least one dose of trial treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.8"}, {"groupId": "OG001", "value": "13.7"}, {"groupId": "OG002", "value": "41.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-29.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.3", "ciUpperLimit": "-19.4"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in percentage", "paramValue": "-28.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.5", "ciUpperLimit": "-18.4"}]}, {"type": "SECONDARY", "title": "Time to Initiation of Glycemic Rescue by Week 26", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days. Below data include data from 1 participant in the Placebo arm who continued Phase A treatment for an additional 30 days.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of trial treatment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Days", "timeFrame": "Up to Week 26 (plus 30 days for 1 placebo participant)", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"title": "Minimum time to initiation of glycemic rescue", "categories": [{"measurements": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "26"}]}]}, {"title": "Maximum time to initiation of glycemic rescue", "categories": [{"measurements": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "147"}, {"groupId": "OG002", "value": "212"}]}]}]}, {"type": "SECONDARY", "title": "Time to Initiation of Glycemic Rescue by Week 52", "description": "Glycemic rescue medication was initiated for participants who met progressively more stringent glycemic rescue criteria. Rescue medication included glimepiride (or insulin glargine if glimepiride was not considered appropriate for the participant). Data presented are the minimum and maximum times to the initiation of rescue therapy in days.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of trial treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Days", "timeFrame": "Up to week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"title": "Minimum time to initiation of glycemic rescue", "categories": [{"measurements": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "26"}]}]}, {"title": "Maximum time to initiation of glycemic rescue", "categories": [{"measurements": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "299"}, {"groupId": "OG002", "value": "327"}]}]}]}, {"type": "SECONDARY", "title": "Baseline Homeostasis Model Assessment of \u03b2-cell Function (HOMA-%\u03b2) Value", "description": "HOMA-%\u03b2 is a well-accepted means of assessing fasting \u03b2-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%\u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\]", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had HOMA-%\u03b2 measurement at baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "140"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.99", "spread": "23.890", "lowerLimit": "8.87", "upperLimit": "17.68"}, {"groupId": "OG001", "value": "48.54", "spread": "34.782", "lowerLimit": "7.94", "upperLimit": "16.93"}, {"groupId": "OG002", "value": "48.04", "spread": "30.733", "lowerLimit": "-4.08", "upperLimit": "5.12"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in HOMA-%\u03b2 at Week 26", "description": "HOMA-%\u03b2 is a well-accepted means of assessing fasting \u03b2-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%\u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\]. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one HOMA-%\u03b2 measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "147"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.28", "lowerLimit": "8.87", "upperLimit": "17.68"}, {"groupId": "OG001", "value": "12.43", "lowerLimit": "7.94", "upperLimit": "16.93"}, {"groupId": "OG002", "value": "0.52", "lowerLimit": "-4.08", "upperLimit": "5.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "12.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.83", "ciUpperLimit": "18.68"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "11.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.94", "ciUpperLimit": "17.88"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HOMA-%\u03b2 at Week 52", "description": "HOMA-%\u03b2 is a well-accepted means of assessing fasting \u03b2-cell function, and is calculated using measured C-peptide and glucose levels and is measured as a percentage of a normal reference population. HOMA-%\u03b2 = \\[20 x fasting insulin (\u03bcU/mL)\\] / \\[fasting plasma glucose (mmol/L) - 3.5\\]. Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one HOMA-%\u03b2 measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "152"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.85", "lowerLimit": "6.29", "upperLimit": "15.41"}, {"groupId": "OG001", "value": "10.93", "lowerLimit": "6.24", "upperLimit": "15.61"}, {"groupId": "OG002", "value": "-1.93", "lowerLimit": "-6.88", "upperLimit": "3.02"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "12.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.54", "ciUpperLimit": "19.03"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "12.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.54", "ciUpperLimit": "19.18"}]}, {"type": "SECONDARY", "title": "Baseline EQ-5D 3-level Version (EQ-5D-3L) Questionnaire Score", "description": "The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 1-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ visual analogue score (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best).", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had a baseline EQ-5D-3L measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "152"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.88", "spread": "0.166", "lowerLimit": "-0.02", "upperLimit": "0.03"}, {"groupId": "OG001", "value": "0.89", "spread": "0.182", "lowerLimit": "-0.00", "upperLimit": "0.04"}, {"groupId": "OG002", "value": "0.90", "spread": "0.144", "lowerLimit": "-0.01", "upperLimit": "0.04"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in EQ-5D-3L Questionnaire Score at Week 26", "description": "The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one EQ-5D-3L measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.02", "upperLimit": "0.03"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "-0.00", "upperLimit": "0.04"}, {"groupId": "OG002", "value": "0.01", "lowerLimit": "-0.01", "upperLimit": "0.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.04", "ciUpperLimit": "0.02"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.04"}]}, {"type": "SECONDARY", "title": "Change From Baseline in EQ-5D-3L Score at Week 52", "description": "The EQ-5D-3L is a health profile questionnaire that assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with \"3\" corresponding to no problems and \"15\" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also includes an EQ VAS that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score is weighted with a range of -0.594 (worst) to 1.0 (best). Data presented exclude data following the initiation of rescue therapy.", "populationDescription": "Analysis population included all randomized participants who took at least one dose of study medication and had at least one EQ-5D-3L measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "lowerLimit": "-0.00", "upperLimit": "0.05"}, {"groupId": "OG001", "value": "-0.00", "lowerLimit": "-0.03", "upperLimit": "0.03"}, {"groupId": "OG002", "value": "0.02", "lowerLimit": "-0.01", "upperLimit": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.04", "ciUpperLimit": "0.04"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Difference in least squares means", "paramValue": "-0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.07", "ciUpperLimit": "0.02"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 54 weeks", "description": "Data presented below includes data following the initiation of rescue therapy for the entire study (ie, all data after randomization, with no upper limit on the follow-up window for participants who discontinued study drug). Two participants randomized to ertugliflozin 15 mg didn't receive any study medication \\& aren't included in the below tables", "eventGroups": [{"id": "EG000", "title": "Ertugliflozin 5 mg (Phase A+B)", "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks", "seriousNumAffected": 13, "seriousNumAtRisk": 156, "otherNumAffected": 24, "otherNumAtRisk": 156}, {"id": "EG001", "title": "Ertugliflozin 15 mg (Phase A+B)", "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks", "seriousNumAffected": 3, "seriousNumAtRisk": 153, "otherNumAffected": 18, "otherNumAtRisk": 153}, {"id": "EG002", "title": "Placebo (Phase A+B)", "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks", "seriousNumAffected": 8, "seriousNumAtRisk": 153, "otherNumAffected": 29, "otherNumAtRisk": 153}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Abdominal pain lower", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Liver disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Bone tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Lymphangitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Meningitis tuberculous", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Subcutaneous abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Bening ear neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Invasive ductal breast carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Hemiplegia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Urge incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 153}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 153}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 153}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 153}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 7, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 11, "numAffected": 5, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 18, "numAffected": 11, "numAtRisk": 153}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 156}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 153}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Bulgaria", "Czech Republic", "Finland", "Hungary", "Israel", "Korea, Republic of", "Malaysia", "Romania", "Slovakia", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}